A journal article reported an association between anti-HBc and NANBH and that a high percentage of NANBH patients develop chronic hepatitis. It concluded that if surrogate screening could prevent approximately one third of transfusion-associated cases of NANBH, this could represent an annual reduction of 50,000 cases of hepatitis and 2,500 cases of cirrhosis in the US.